Clinical Trial Update: Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA [Phase 1]

View source ↗

Summary

Phase 1 clinical trial is recruiting for a DNAJB1-PRKACA fusion peptide vaccine intended for fibrolamellar hepatocellular carcinoma and other tumors expressing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma

Drugs mentioned

• DNAJB1-PRKACA fusion peptide vaccine

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Fibrolamellar Hepatocellular Carcinoma (FLC) | Phase 1 | Status: RECRUITING